NCT04910022
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Per the protocol, the sponsor reserves the right to discontinue the trial for valid scientific or administrative reasons. The discontinuation of the study is not related to safety issues. Show 5 more changesShow less
- Eligibility criteria expanded, about 40 words
- Trial sites reduced: 18 → 12 locations
- Final enrollment: 80 participants (planned 150)
- Primary completion date changed from estimate of May 30, 2027 to May 6, 2026
- Secondary endpoints: details revised at 6 of 20 entries
- Notable Primary completion date: Jun 30, 2025 to May 30, 2027
- Study completion date: Nov 30, 2025 to Sep 7, 2027
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 18 of 18 sites
- Minor Study sites: 11 to 18v9
- Minor Study sites: 10 to 11v8
Show 6 earlier versionsHide 6 earlier versions
- Minor Study sites: 5 to 10v7
- Notable Enrollment target: 75 to 150
- Eligibility criteria expanded, about 309 words
- Secondary endpoints: details revised at 11 of 20 entries
Notable Enrollment target: 125 to 75v5 Show 5 more changesShow less
- Eligibility criteria expanded, about 74 words
- Primary endpoints revised (2)
- Interventions: Lomustine (Drug), NMS-03305293 + TMZ (Drug), NMS-03305293 + TMZ (Drug), NMS-03305293 + TMZ (Drug) to NMS-03305293 (Drug), Temozolomide (Drug)
- Secondary endpoints: 18 to 20
- Study arms: 4 to 1
- Minor Study sites: 4 to 5v4
Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
- Primary completion date: Dec 31, 2024 to Jun 30, 2025
- Study completion date: May 30, 2025 to Nov 30, 2025
- Start date changed from estimate of Sep 30, 2021 to Dec 1, 2021
- Site details revised at 4 of 4 sites
- Notable Start date: May 28, 2021 to Sep 30, 2021v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (20)
Show 15 moreShow less
Arms and interventions
Phase 1 Dose Escalation: All patients will receive NMS-03305293 and temozolomide (TMZ) administered orally (NMS-03305293 once or twice daily on days 1-7 or 28 consecutive days from Day 1 to Day 28; TMZ once daily on days 1-5;) in repeated 4-week cycles aimed at defining the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Doses (RP2Ds) of NMS-03305293 in combination with TMZ. Each cycle is 28 days. Phase 2: Once the RP2D is defined, the patients will receive TMZ daily on days 1-5 in combination with NMS-03305293 at the RP2D on days 1-7 or on days 1-28 every 28 days. Backfill cohorts: additional patients may be treated with TMZ daily on days 1-5 and NMS-03305293 at different dose levels/schedules that have been previously assessed and determined to be safe, in order to properly characterize the exposure relationship over a range of doses/schedules. The backfill cohorts may run in parallel.
Drugs: NMS-03305293, Temozolomide
Sites
12 sites in 4 countries
United States 7, Italy 3, Netherlands 1, Switzerland 1